SNAPSHOT OF PROGRESS

2012-2013

1101 New York Avenue NW, #620 Washington, cDC,urem 20009elanoma.org It’s been a year of exciting collaborations that connect multiple research programs with critical investments. The Melanoma Research Alliance (MRA), a unique foundation launched by Debra and Leon Black under the auspices of the Milken Institute, works to accelerate scientific discovery to eliminate death and suffering due to melanoma. Over the past year, MRA has worked tirelessly to achieve this goal, aided by scientific researchers, funders, corporate and non- profit allies, and volunteers.

To date, MRA has awarded more than $49 million in funding to 118 innovative, translational research programs led by 171 Principal Investigators at 80 institutions in 14 countries. In August 2013, MRA released its latest Request for Proposals with plans to award at least $8 million (in the spring of 2014) including its first regional special opportunity. A key component of MRA’s unique research program emphasizes collaboration within and across sectors.

The melanoma landscape is evolving quickly, and the foundation has been laid for new, more successful approaches to treat this deadly cancer. As a result, there is unprecedented opportunity for transformational progress on behalf of patients, and all who are at risk, with more than 100 new melanoma compounds in the pipeline and nearly 300 clinical trials underway.

MRA also runs multiple awareness campaigns to promote sun safety and encourage early melanoma detection. The work of our allies plays a key role in new prevention and early detection efforts, amplifying our message.

With all of these diverse stakeholders committed to fighting melanoma on multiple fronts, we are optimistic that the day when no one will suffer or die from melanoma is within reach.

Debra Black Wendy K.D. Selig Co-Founder and Chair President and CEO

Melanoma Research Alliance Progress Report 1 www.curemelanoma.org Scientific Update

In six years of grant making, MRA has committed more than $49 million to 118 research programs with the potential to make significant, near term clinical impact in melanoma prevention, diagnosis, staging and treatment. MRA is the largest private funder of melanoma research, catalyzing transformative, strategic, and collaborative investments in scientific discovery and translation.

Recent years have seen unprecedented progress in the melanoma treatment space. Over the past three years, five new melanoma agents have won approval from the US Food and Drug Administration (FDA). With increasing knowledge about the mechanisms that underlie melanoma initiation and growth, researchers, clinicians, and industry leaders are exploring multiple single agent and combinatorial approaches to combat this aggressive disease. The dramatic acceleration of the pace of discovery occurring today in melanoma is also fueling progress in other malignancies, making melanoma a “case study” for new approaches to therapy.

MRA research funding per year Leveraged funding $50 2013 $100

$90 $40 $10.6 $80 $47M 2012 Leveraged $7.9 $70 $30 Funding 2011 $60 $8.4 $50 2010 $20 $40 $5.9 $49M MRA $30 2009 (Millions) Impact Investment

Total Funding (Millions) Funding Total $10 $8.6 $20 2008 $10 $7.6 $0 $$-0

With more than $10 million awarded in 2013, MRA set a new record for funding. With its founders’ generous support of all administrative and fundraising

Melanoma Research Alliance Progress Report 2 www.curemelanoma.org expenses, MRA directs 100% of all donations to research. MRA now supports 40 Young Investigators, is engaged in eight Academic-Industry Partnership Awards with a variety of pharmaceutical, biotech, and device companies, and co-funds a Melanoma Dream Team award with Stand Up to Cancer (SU2C).

Outcomes

In just a few years of active research, the productivity of MRA-funded investigators has been high, as measured by tangible outcomes and promising early research results.

By the Numbers (as of December 31, 2013):

 More than $47 million in additional research funding leveraged from other sources by MRA investigators. The majority of this funding was granted by the U.S. National Institutes of Health and other foundations.

 18 clinical trials supported by MRA to test promising agents alone and in combination for the treatment of metastatic melanoma.

 17 patent applications filed or new inventions disclosed for new technologies, which have the potential to be developed into new tools or treatments for patients.

 More than 100 papers published in high impact journals describing research results supported by MRA, which inform the scientific and clinical communities about promising new research findings so that others may build upon the results to help patients.

 More than 145 collaborations initiated and strengthened between academic, government, and industry scientists, which enhance sharing of information and fast-forwarding the research.

 Approximately 450 presentations delivered by MRA investigators at medical and scientific meetings in the U.S. and internationally, where research results are shared, further raising MRA’s profile.

Melanoma Research Alliance Progress Report 3 www.curemelanoma.org Top Funded Scientific and Clinical Areas

The majority of MRA funding supports the development of new treatment approaches, including the following specific areas:

 BRAF inhibition: MRA has provided more than $11 million in research funding to projects involving elucidating resistance mechanisms and combining BRAF inhibitors with other agents.

 Immune checkpoint targeting: MRA has provided more than $10 million in funding to projects aiming to improve ipilimumab or anti-PD-1 immunotherapy through identification of biomarkers associated with response and non-response and combining these agents with other therapies.

 Combinatorial therapies: MRA has provided more than $11 million in funding for developing combinations of molecularly targeted agents, immunotherapies, small molecules and biologics, as well as combination therapies involving surgical and radiological approaches.

Immune checkpoint Other molecular targets blockade (CTLA-4/PD-1) (not BRAF), vaccines, cell therapy, other

BRAF inhibition

Melanoma Research Alliance Progress Report 4 www.curemelanoma.org Event & Outreach Highlights

MRA’s fundraising events allow the organization to connect with supporters and bring together its diverse constituencies. Multi-platform awareness activities and alliances help MRA spread the message of melanoma prevention and sun safety.

Leveraged Finance Fights Melanoma

The second annual Leveraged Finance Fights Melanoma fundraising and networking event was held May 21, 2013, in ’s Rockefeller Center. More than 800 attendees from the leveraged finance community and related fields spent the evening networking and raising funds for MRA’s melanoma research. The event and silent auction generated more than $1.2 million. Featured speakers included Co-Hosts Jeffrey Rowbottom of KKR and Brendan Dillon of UBS, MRA founder Debra Black, and a special video address by MRA Board Member Michael Milken.

New York Stock Exchange (NYSE) Closing Bell Ceremony

MRA had a unique and impactful opportunity to raise awareness about its mission to defeat melanoma this summer, when MRA rang the Closing Bell of the New York Stock Exchange (NYSE). Surrounded by MRA leadership and supporters, MRA Co- Founder and Chair Debra Black rang the bell on the NYSE trading floor on Tuesday, June 25th.

Melanoma Research Alliance Progress Report 5 www.curemelanoma.org Melanoma Awareness Month

In celebration of Melanoma Awareness Month each May, MRA engages in multifaceted outreach and fundraising campaigns with its May allies. This year’s activities included a record number of corporate and non-profit partners who helped fundraise for MRA and spread the organization’s message of sun safety and melanoma awareness.

May partners Claire’s and Sports Authority collected donations for MRA at their cash registers and worked to educate their customers on melanoma detection and prevention. Some allies donated a portion of sales from sun-safe merchandise to MRA, while others engaged with MRA on social media, helping to amplify MRA’s messaging.

Outreach and Fundraising Campaigns

MRA and L'Oréal Paris announced a new alliance on Melanoma Monday with plans for L'Oréal Paris to donate $1 from each sale of a Sublime Sun SPF product to MRA, in support of an MRA Team Science Award. The Sublime Sun outreach campaign encompassed traditional and social media and helped raise awareness of melanoma prevention and safe sun habits.

The organization also teamed up with The American Idol® Live! Tour 2013. The Tour donated $1 from every ticket sold to MRA’s research programs and MRA was featured in promotional materials, as well as the printed concert program. MRA and the Tour also teamed up with celebrity fundraising platform Prizeo to launch an innovative fundraising contest that offered fans of American Idol® a money-can’t-buy VIP Tour experience. This social media and fan-driven fundraising concept is just one example of how MRA pursues innovative outreach strategies.

Melanoma Research Alliance Progress Report 6 www.curemelanoma.org Financials (as of 12/31/12)

Thanks to the generous financial support of MRA’s founders for administrative and fundraising expenses, 100 percent of donations to MRA directly support melanoma research. The independently audited financial statements of the Melanoma Research Alliance Foundation form the basis of the following information:

MRA Statement of Activities for Year Ended December 31, 2012

2012 2011 Temporarily Unrestricted Restricted Total Total REVENUES, PUBLIC SUPPORT AND OTHER INCOME: Contributions $1,681,786 $1,982,816 $3,664,602 $20,886,477 Special Events 3,299,167 1,367,499 4,666,666 - Sponsorships 207,500 - 207,500 127,000 Interest Income 29,985 - 29,985 21,414 Other Income 54,500 - 54,500 - In-Kind Contribution 69,178 - 69,178 - Net Assets Released from : Purpose Restrictions 1,040,206 (1,040,206) - - Time Restrictions 2,587,723 (2,587,723) - -

TOTAL REVENUES, PUBLIC $8,970,045 ($277,614) $8,692,431 $21,034,891 SUPPORT AND OTHER INCOME

FUNCTIONAL EXPENSES: Program Services 8,476,752 - 8,476,752 6,024,335 Management and General 375,042 - 375,042 262,558 Fundraising 485,653 - 485,653 369,545

TOTAL FUNCTIONAL EXPENSES $9,337,447 - $9,337,447 $6,656,438

CHANGE IN NET ASSETS (367,402) (277,614) (645,016) 14,378,453

Net Assets - Beginning of Year 9,760,006 21,221,550 30,981,556 16,603,103 NET ASSETS - END OF YEAR $9,392,604 $20,943,936 $30,336,540 $30,981,556

Melanoma Research Alliance Progress Report 7 www.curemelanoma.org MRA Statement of Financial Position for Year Ended December 31, 2012

2012 2011 Temporarily ASSETS Unrestricted Restricted Total Total Cash $9,824,412 $1,137,282 $10,961,694 $10,332,793 Accounts Receivable - - - 44,375 Contributions Receivable (Net) - 19,806,654 19,806,654 20,439,692 Prepaid Expenses and Other Assets 81,832 - 81,832 508,274 Property and Equipment (Net) 27,278 - 27,278 6,109 TOTAL ASSETS $9,933,522 $20,943,936 $30,877,458 $31,331,243

LIABILITIES AND NET ASSETS LIABILITIES: Accounts Payable and Accrued Liabilities 169,505 - 169,505 139,051 Deferred Revenue 50,000 - 50,000 70,000 Due to Affiliate 321,413 - 321,413 140,636 TOTAL LIABILITIES $540,918 - $540,918 $349,687

NET ASSETS: Unrestricted $9,392,604 - $9,392,604 $9,760,006 Temporarily Restricted - 20,943,936 20,943,936 21,221,550 TOTAL NET ASSETS 9,392,604 20,943,936 30,336,540 30,981,556

TOTAL LIABILITIES AND NET ASSETS $9,933,522 $20,943,936 $30,877,458 $31,331,243

Melanoma Research Alliance Progress Report 8 www.curemelanoma.org 2012 Functional Expenses

Grants and Awards Program $ 8,003,206 Non-Grants Scientific Program $ 473,546 Fundraising $ 485,653 Management and General $ 375,043

Management & General Fundraising Non-Grants 5% 4% Scientific Program 5%

Grants & Awards 86%

Melanoma Research Alliance Progress Report 9 www.curemelanoma.org Donors & Supporters (January 1, 2012 – December 31, 2012)

$500,000↑

Akin Gump Strauss Hauer & Feld LLP* Hess Foundation, Inc. * The Jeffrey A. Altman Foundation* Nancy and Howard Marks* Anonymous O'Melveny & Myers LLP* Debra and Leon Black* The Stewart J. Rahr Foundation* Bloomberg Philanthropies* The Ressler Family Foundation* Christie's* Sokoloff Family Trust* Jami Gertz and Tony Ressler*

$250,000-$499,999 The Bell Family Foundation, Inc. * Latham & Watkins LLP* Jill and Jay Bernstein* PricewaterhouseCoopers* Bristol-Myers Squibb Company* The Lawrence and Carol Saper Foundation * Brownstein, Hyatt, Farber & Schreck* Elizabeth and Oliver Stanton Foundation* The Carson Family Charitable Trust* US Trust, Bank Of America* Credit Suisse* Wachtell, Lipton, Rosen & Katz* Ellen and Gary Davis Foundation*

$100,000-$249,999 Anonymous Genentech, Inc. Aon* Daisy Helman Katie and Todd Boehly* Suzette and Steven Kolitch* Cartier* Jo Carole and Ronald Lauder Claire's Morgan Stanley* * Sotheby's Amanda and Jonathan Eilian* The Viola Fund* *Multi-year donor

Melanoma Research Alliance Progress Report 10 www.curemelanoma.org $50,000-$99,999

The Daniel & Estrellita Brodsky Family Dominique Levy and Dorothy Berwin Foundation Mintz, Levin, Cohn, Ferris, Glovsky and Sunny and Norm Brownstein Popeo, P.E. * Caryl and Israel Englander Paul, Weiss, Rifkind, Wharton & Ernst & Young LLP* Garrison LLP Foundation 14 Nancy and Richard Rogers Larry Gagosian Lizanne and Barry Rosenstein Goldman Sachs & Co. Nancy Silverman Judith and John Hannan SkinCeuticals George Klein Katherine and Jerry Speyer The Marie-Josée & Henry R. Kravis Foundation

$25,000-$49,999 Adele and Beny Alagem Eli Lilly and Company Apollo Management, LP Andrea and George Ferris Abbe and Adam Aron Gibson, Dunn & Crutcher LLP Debbie and Mark Attanasio Jane Goldman and Ben Lewis Aurora Capital Group Hazen Polsky Foundation Lidia M. Bastianich Gail and Carl Icahn Emily and Len Blavatnik Kirkland & Ellis LLP BMO Capital Markets David L. Klein, Jr. Foundation Cahill Gordon & Reindel LLP Kohlberg Kravis Roberts & Co. Celgene Bennett LeBow Citi Raymond Lin Joyce and Barry Cohen Morgan, Lewis & Bockius LLP

*Multi-year donor

Melanoma Research Alliance Progress Report 11 www.curemelanoma.org Novartis Corp. Susan and Eric Smidt Robin and Gerald Parsky Mary and David Solomon Paul Hastings Sports Authority The Raiff Foundation Ronald Stanton James O. Robbins Family Charitable The Thompson Family Foundation Lead Annuity Trust Meryl and James Tisch Carolyn and Marc Rowan UBS Fran and Jeff Rowbottom Maureen White and Steven Rattner Simpson Thacher & Bartlett LLP Leslie and Daniel Ziff

$5,000-$24,999

Marcia and Greg Abbott Davis Polk & Wardwell Aduro Biotech Jeanine Depasquale Salvatore and AdvaMedDx Louis Salvatore Amgen, Inc. Deutsche Bank Krista and Devon Archer Barbaralee Diamonstein Spielvogel Babson Capital Management LLC and Carl Spielvogel Bank of America Merrill Lynch Susan Drossman and Adam Sokoloff Barclays Capital Eaton Vance Melissa and Dror Bar-Ziv Entertainment Industry Foundation Rebecka and Arie Belldegrun Richard Farley Lawrence Benenson First Republic Bank Bergdorf Goodman, Inc. Fitch Ratings Caris Science, Inc. Scot French Thomas Cole Beth and Joshua Friedman Thomas Connolly GE Capital Crescent Capital Group GoldenTree Asset Management, LP

Melanoma Research Alliance Progress Report 12 www.curemelanoma.org Goldman Sachs Gives Earle Mack The Joshua and Marjorie Harris Family Macquarie Group Foundation Ares Management LLC Leland Hart Alison Mass and Sal Bommarito HCA Holdings Steve Miller Marlene and Paul Herring Mizuho Securities USA, Inc. Ronnie Heyman MJX Asset Management, LLC Tania and Brian Higgins Charitable Trust Julie and Kenneth Moelis Highbridge Capital Management, LLC Natixis Global Asset Management Caroline Hirsch and Andrew Fox Patty Newburger and Brad Wechsler HSBC Bank Kate and Robert Niehaus Illumina, Inc. Oak Hill Advisors, LP Jefferies & Company, Inc. Marc Packer Pamela Joyner and Alfred Giuffrida Pfizer, Inc. JPMorgan Chase & Co. Provectus Pharmaceuticals, Inc. Jill and Harry Kargman Bonnie and Richard Reiss Laurie Kefalidis Daryl & Steven Roth Foundation Kelly's Dream Royal Bank of Canada Cheryl and A.B. Krongard Shearman & Sterling LLP Ashley Leeds and Christopher Harland Shenkman Capital Management, Inc. Almedena and Pablo Legorreta Andree and Howard Shore Life Technologies Corporation Shannon and G. Christopher Smith Milan Lint Sony Music Chauncey F. Lufkin SpaFinder, Inc. Luxembourg Dayan Standard & Poor's Carol Lynton and Michael Ryan Lindsay and Peter Stavros Peter Lyon David Stockman

Melanoma Research Alliance Progress Report 13 www.curemelanoma.org Adele Thurnher Mindy and Marc Utay Alice and Thomas Tisch Carol Wall Tourneau, Inc. Deborah and Jeffrey Webber Diane and Tom Tuft Wells Fargo Bank Turk Family Foundation White & Case LLP

$1,000-$4,999

Catherine and Christopher Abbate Nancy and Albert Kotite Lawrence Alletto Adam Kurzer Vadim Berman Shau-wai Lam Barbara and James Block Karen and Richard LeFrak Katherine Boden Holland Chris Majak Fred Brettschneider Nancy Cain Marcus Timothy Broadbent Jill and Tom Marino Brendan Dillon John McAuley Craig Farr The Joseph and Christine McGrath Sara Ferchichi Charitable Fund Lynn and Mark Filipski The Robert and Joyce Menschel Peter Glaser Family Foundation Andrea and James Gordon Kirstin and Carl Meyer Kathy and Alan Greenberg Milbank Tweed Hadley & McCloy LLP Kristy and Robert Harteveldt Montage Hotels & Resorts Katrin and Christoph Henkel George Mueller Christopher James Nederlander Of New York, Inc. Maury Kaplin Dawn and Mark Ostroff Erica and Mike Karsch John Pearce

Melanoma Research Alliance Progress Report 14 www.curemelanoma.org The Pevaroff Cohn Family Foundation The Tea Lab LLC Jill and Mark Rachesky Fern and Leonard Tessler Jonathan Ressler W. Cade Thompson Marcia Riklis Christopher Torrente Nancy Risman Kathryn Trappey Hilary and Wilbur Ross Mary Lynn van Wyck Christopher Rulon-Miller Leon Wagner Stephen Sander Harriet and Ronald Weintraub Wendy and Michael Selig Carol and Michael Weisman Nicole and Joel Seligman David Wirdnam Frank Sica Rose and James Wolfe Paul Sohn Brian Yorke Harold Sokoloff John Zapas Ann and John Sorice Reed Zaroff Debora and James Staley Bonnie Ziegler Steel Partners Foundation Richard Zogheb Denise and Tom Stern

↓$1,000

Jeff Abt Sam Astor Grant Barmby Heidi Adkins Sharyar Aziz Jeannette Barry Sura Alammar-Rathor Carmen Bailey Alexandra Barth Scott Anderson Cecile Baker Luke Bartolone Virgil Anderson William Balassone Mark Basile Robin and Paul Appleby Penelope Balzereit Nomi and Peter Bass William R. Arniel Charles Barbato Priscilla and David Baum Penny and Mitchell Arons Hannah Bargad Janice Bausch

Melanoma Research Alliance Progress Report 15 www.curemelanoma.org James Beaubien Jamie Brodsky Todd Corsair Barbara and Clyde Beck Joyce Brown Kathleen Coverick Carl Becker Tom Brown David Crall Loren Becker Michael Buchanan Andrew Crenshaw Ron Beit Halachmy Vaughn Buck Crispin Porter + Bogusky Nicole Beit-Halachmy Susanne Bull Jason Cunningham Susan and Alan Bennett Scott Bynum Helene and Laurence Cutler Chetan Bhandari Jeanette Cacciola Michael Damaso Mercedes and John Barbara Caldarone Barbara Davis Biedermann W. Jane and Simon Canning Mary Davis Lydia and David Bigner Lynn Cannizzaro Kyle Decker Ann Marie Birns Natalie Carrol Lauren and Armand Della Lisa Blanchard Joseph Castiglia Monica Marcy Bledsoe-Bouton Andrew Cates Andrew DeNatale Brenda and Charles Block Marian and John Celentano Lisa Dennison The Blue Oak Charitable Adam Chai Brooke Denton Fund Jenny Chan Wit Derby James Boland Michelle Chmelar Deborah DeSantis Michelle Bondarchuk Rob Cignarella Sandra DeWoody James Bonetti Thomas Cimino Aashish Dhakad Cecilia Bonn Cara Cisciari Jeanne Dietrich Katherine Boothby Citi Habitats Derek Dillon Katia Bouazza Laurie Cohen-Fenster and Courtney Dougherty Karen and Gordon Philip Fenster Cohen Douglas Braverman Sylvia Cohn Ann-Lynn and Robert BRELLI Kyong and Brad Coleman Drossman Jill H. Breneman David Colla Chris Droussiotis Christopher Brescio Jason Colodne John Duggan Jose Briones Carlene and Fred Condon Robert Dymowski Nancy Broadbent Kristen Condon Andrew Edgell Linda Brockman James Connolly Butch Elias

Melanoma Research Alliance Progress Report 16 www.curemelanoma.org Karen Eltrich William Gates Damon Hall Dorothy and John Vicki and Gerald Geist Susan and Alan Hammer Engelbrecht Robert Germain David Handelman Equinox Jilli Getz Todd Harkrider Hugh Evans Scott Giardina Philip Harris Francesca Fabri Joanne Gillespie Harvard Community Gifts Susan and Joseph Facenda Linda and Bob Ginsburg David Hauck Timothy Fazio Krista Giovacco Kristen Haunss Ruth and Arthur Feder Annette Gladstein Victor Hazan Elizabeth Feiner Brian Goldberg Penny Hecht Michael Fenstermacher Craig Goldstein Jan Hoffman Craig Fitt MIchael Goldstein Vanessa Hogge Beverly and L. Carl Fletcher Mitchell Goldstein MK Houston Ashley Fodor Ronnie Goldstein Thomas Howard Lawrence Fohrman Betsy Gonsalves Renee and William Hughes James Forbes Dev Gopalan George Hunt Char and Chuck Fowler Andrew Gordon Grace Hwang David Fox Janette and Joel Granet Phyllis Hyde Ira Fox Erin Grant James Incognito Alyssa Frey Valisha Graves Philip Ittleson Rondi and David Frieder Rachel Greene Walter Jackson Mary Jane Fritsch Carolyn and Victor Groisser Matt Janchar Daniel Frommer Brian Grossberg Kelvin Ji Janet Fryer Marlyn Grossman Emily Johnson Diane and David Gaietto Jeffrey Groves Sarah Johnson Eileen and Vincent Gaietto Wendy and David Guda Geoffrey Jones Barry Gainsburg Greg Guest Ruth Jones James Galowski Giri Gururaja James Joyce Marie Garcia Elyse Gutman Joan Joyce Mary Ellen Garrigue Noreen Haider Sally Joyce Ray Garson Sadia Halim Sean Kadden

Melanoma Research Alliance Progress Report 17 www.curemelanoma.org Allison Kaiser Bret Leas Gregory Mason Frances Kaminski Chad Leat Linda Mastrone Walter and David Kaner Jeanne Lebuhn Barbara Matas Jason Kanner William Lemberg Gregory Mathis Harriet and Warren Chris Lentz Lily-Jean Mazur Kantrowitz Letarte Retail Greenwich LLC Kait McCann David Kaplan Jonathan Leu Patricia McCollum Nick Karsiotis Weihun Leung Kay and Roger McCulley Ann Kasenchak Greg Levi Mike McEntee Seth Katzenstein Sheila and Howard Levine Kenneth McGray Amy and Jacob Kaznel Andrew Levinson Peter McKillop Theresa and Marvin Keefe Linda and Paul Levy Louis Meltzer John Kilgallon Rob Lewin Joan and Alfred Miller Edward Kim Shari and Chip Lisann Jacqueline Miller Julie Kim John Livingston James Miller Nelle and William Kinney Kevin Lockhart Marjorie Miller Monica Kirmayer Barbara Lorenz Sage and Anthony Minella Lisa Klein Donna Loupus Steven Mitchell Nancy and Joshua Korff Audrey Lucker Cynthia S. Monroe Paul Kormondy Eric Luftig Moore-Tanne Foundation Iris and Hal Korol Ellen Luntz Marianne Mordhorst David Kroner R.J. Lutze Joseph A. Moroney Lisa and Harvey Lambert Blaine MacDougald Gary Moross Stephanie Landers Joseph T. Madden Joan and Allan Morris Katerina Lardas Coleen Mager William J. Morrison Jill and David Lascher Marion and Allan Maitlin Michael Movsovich Julie and Rick Laux Marilyn and Joseph Maltz Brianne Mulligan Ed Law Ellen Manheimer Ryan Munro Christopher Lawler Maria and Daniel Marano Ramzi Musallam Mark Lawrence Maris Grove Players Rita and Jack Nadler Michael Lawton Suzanne and Martin Marvin Christian Nagler

Melanoma Research Alliance Progress Report 18 www.curemelanoma.org Kathleen Nash Shirley Pilote Ivan Rodriguez Network For Good Michael Pineau Mae Rogers Jonathan Neumann Francisco Pinto-leite Kara Romeo New Jersey State Association Rachel Plafker and Dave Esrig Daniel M. Rosen Lila M. Newman Stephen Plocher Kim and Jeffrey Rosen Matthew Nord Kevin Pluff Dara and David Rosenberg Chris Nordsiek Sandhini Poddar Marybeth Ross Jay Nussbaum Justin Polselli David Rowland Patrick Obringer Alexander Popov Jayme Rubright Occupational Assessment Maggie Porges Valerie Ruckert Services New Jersey, Inc. Kristen Posluszny Michael Russo Lee Olive Carol and Jeff Press Christopher Ryan Betty and William Orbinger Joel Pruis Mike Ryan Susan Osborn Karen and Jay Ptashek Lisa Ryll Matthew Osborne Peter Pulkkinen Carol and Edward Sacks David Oscar Michael Quadrino Nara Sadagursky Dennis Papathanasopoulos Kirk Radke Arthur Saitta Nicholas Pappas Robert Rahr Peter Sakon Christian Paragot-Rieutort Steven Reed Phyllis Samaan Robert Parker Beatrice Rehl and Richard James Samuelson Marrianne and Bruce Etlin Geri and Neal Sanderson Parkinson Georgina Reid Andrew Sargison Marguerite E. Parkinson Summer Rej Janet and Amos Saunders Linda and Louis Pashman Monique Renta Paul Savas Alvina Patel Kathy and Tim Reynolds Matthew Savino Vaishali Patil Reagan Ridgell Glenn Schembri Alison and Steven Pearlman Jason Ridloff Linda and Harvey Schilowitz Helene Penido Thomas Ringel Heather Schmidt Judith and Kenneth Peskin Jessica Ritt Joseph Schneider Sean Peters Michelle and Michael Lyn and Bruce Schnelwar Robert Pierson Roberts Jean Schopps

Melanoma Research Alliance Progress Report 19 www.curemelanoma.org Paula and Robert Schopps David Sorkin Edward Vietor Antoinette and Newton Arnold and Linda Stadtmauer Vimas NY, Inc. Schott Elissa and Alan Stapansky Justin P. Walder Marcie and Douglas Schubert Scott Stearns Anne Walker Kenneth Schweber Mark A. Stegemoeller Andrew Wallach David Scudellari LauraSue and Marc Steinman Betty Walters Neil Shah Lee Stern Bette and Alan Walton Paul Sharkey Glenn Stewart Jeff Warren Anja Sharma Jone Stewart Laurie E. Watrous I.M. and Elizabeth Sheaffer Carol Stoliar Clifford Weininger Josephine Sherwood Ricki and Matt Stoltz Bernard Weinstein Eleanor Shireling Matthew Stopnik Charitable Lead Trust Daniel Shirley Allen Susser Melinda Weir Ashley Siebert Adam Suttin Alison Weiss Michael Silver Elinor Sutton Mitchell Weiss Howard Singer Elaine Swain Colleen Weisz Lawrence Skara Jenni Swan Ronald Wells Gloria and Joseph Skurla Ed Tam Theatrice Westbrook Betty and Max Slipman Peter Tamaro Jeremiah Whiddon Jason Slosberg Heather Tancredi Laurie Whitehouse Daniel Slotkin Jeff Teach Ronan Wicks Betty and Robert Smiley Mary Thory Laura Wiesler Wade Smith Mark Thovson Christina Wilder Susan and Martin Soger Chris Tice Scott Willard Mitali Sohoni Jason Tuchman Peter W. Williams Brook Solliday Yolanda Turocy Stephen Winikoff Christopher Solomon Thomas Uger Nicholas Wise Julie Solomon Andrew Ulman Ben Wu Benjamin Son Judith and Paul Umansky Charles York P Sonza Rosa Vargas Robert Zatta William B. Sorabella Ryan Vetsch Garine Zerouni

Melanoma Research Alliance Progress Report 20 www.curemelanoma.org In-Kind Supporters and Allies

Aduro Biotech Celldex AdvaMed Dx Christie's Alliance for a Stronger FDA Citi AltaMarea Group Claire's Altor Biosciences COOLA American Academy of Dermatology Daiichi Sankyo American Idol Live! 2013 Tour Danny Fund Amgen Day Spa Association Anreder & Company Dom Perignon AOL Double Cross Vodka AT&T Eli Lilly Axcess Luxury & Lifestyle Embassy of Australia BeautySage EntroGen Bergdorf Goodman Equinox Biotechnology Industry Organization Eric Javits Birds Nest Foundation FasterCures BJ's Wholesale Club, Inc. First Aid Beauty Bloomberg L.P. GAJA BRELLI Genentech Bristol-Myers Squibb Graff Brownstein, Hyatt, Farber & Schreck Hazen Polsky Foundation Bullfrog Health Research Alliance Cabana Life Hess Corporation Canadian Cancer Society illumina Cancer Research Institute James Perse Canfield Scientific Kelly's Dream Caris Lifesciences Le Metier de Beaute Cartier Life Technologies Celgene L'Oreal Paris

Melanoma Research Alliance Progress Report 21 www.curemelanoma.org Marissa Aplerin Studio Scott Conant Mgmt / Scarpetta Martha Stewart Sirius XM Melanoma Research Foundation SkinCeuticals Montage Hotels Sony Mott 50 Sotheby's National Coalition for Cancer Research Spa Finder National Council on Skin Cancer Prevention SPF Love National Pharmaceutical Council Sports Authority Novartis Stand Up to Cancer O'Melveny & Myers LLP Studio3 Parasol The Milken Institute Pentagram Total Woman Gym & Spa Personalized Medicine Coalition Tourneau Pfizer United for Medical Research PhRMA US Trust, Bank of America PricewaterhouseCoopers Van Wyck Privcap LLC Vineyard Vines Provectus WellNEST Research!America YouBeauty

MRA Staff

Wendy K.D. Selig President and CEO Louise M. Perkins, Ph.D. Chief Science Officer Laura M. Brockway-Lunardi, Ph.D. Scientific Program Director Lauren C. Leiman Director of Marketing and Development Alexandra Carney Scientific Program Manager Ilyona Carter Executive and Operations Manager Jennifer Engel Development Manager Marissa Maybee Communications and Outreach Manager Henry Woodside Database Manager

Melanoma Research Alliance Progress Report 22 www.curemelanoma.org Board of Directors

Maria Bell Richard Ressler Principal and Founder Debra Black, Chair CIM Group Co-Founder Melanoma Research Alliance Jeffrey Rowbottom Managing Director Leon Black Kohlberg Kravis Roberts & Co. Apollo Management LP Elliott Sigal, MD, PhD Ellen Davis Former, Executive Vice President & Chief Founder and Chairman, JCC Greenwich Scientific Officer President, UJA Greenwich Bristol-Myers Squibb

Jason Federici Greg Simon CEO Jami Gertz Poliwogg Movie and TV Actress Jonathan W. Simons, MD Susan Hess CEO and President Prostate Cancer Foundation Michael Klowden President Jonathan Sokoloff Milken Institute Managing Partner Leonard Green & Partners, L.P. Connie Mack, III Retired US Senator (R-FL) Liz Stanton Liberty Partners Group President Elizabeth and Oliver Stanton Foundation Nancy Marks Philanthropist Margaret Anderson, Secretary Executive Director Cindy McCain FasterCures Chairman Hensley & Company Kamyab Hashemi-Nejad, Treasurer Director of Finance Mike Milken Milken Institute Chairman, Milken Institute

Melanoma Research Alliance Progress Report 23 www.curemelanoma.org Scientific Advisory Panel Michael Giordano, MD Suzanne Topalian, MD – Chair Senior Vice President Oncology and Professor of Surgery and Oncology, Johns Immunosciences Development Hopkins Medicine Bristol-Myers Squibb Director, Melanoma Program, Sidney Kimmel Comprehensive Cancer Center Jeffrey Legos, PhD Johns Hopkins University Medicines Development Leader GlaxoSmithKline James Allison, PhD Chairman, Department of Immunology Donald Morton, MD Director, Immunotherapy Platform Chief, Melanoma Program Deputy Director, David H. Koch Center for Director, Surgical Oncology Fellowship Applied Research of Genitourinary Cancers Program University of Texas MD Anderson Cancer John Wayne Cancer Institute Center Neal Rosen, MD, PhD Christopher Austin, MD Enid A. Haupt Chair in Medical Oncology Director, National Center for Advancing Memorial Sloan-Kettering Cancer Center Translational Sciences National Institutes of Health Steven Rosenberg, MD Chief, Surgery Branch Boris Bastian, MD National Cancer Institute Clinical Professor Department Dermatology Mace Rothenberg, MD University of California, San Francisco Senior Vice President Clinical Development & Medical Affairs Paul Billings, MD, PhD Pfizer Inc Chief Medical Officer Life Technologies Joshua M. Sharfstein, MD State of Maryland Gideon Bollag, Ph.D. Secretary of Health and Mental Hygiene Chief Executive Officer Office of Secretary Plexxikon, Inc. Department of Health & Mental Hygiene

Lynda Chin, MD Ellen Sigal, PhD Professor; Chair, Dept of Genomic Medicine Chairperson and Founder Scientific Director, Institute for Applied Friends of Cancer Research Cancer Science, University of Texas MD Anderson Cancer Steven Stein, MD Center Head US Clinical Development and Medical Affairs Richard Gaynor, MD Novartis Oncology Vice President, Oncology, Product Development and Medical Affairs Michael Weber, PhD Eli Lilly and Company Director, Cancer Center, Weaver Professor of Oncology, University of Virginia

Melanoma Research Alliance Progress Report 24 www.curemelanoma.org Medical Advisory Panel

Paul Chapman, MD– Chair Patricia LoRusso, DO Attending Physician, Melanoma/Sarcoma Director, Eisenberg Center for Experimental service, Memorial Sloan-Kettering Cancer Therapeutics; Professor of Medicine, Center Barbara Ann Karmanos Cancer Institute Professor of Medicine, Weill Medical College of Cornell University Kim Margolin, MD Professor, Department of Medicine David Fisher, MD, PhD University of Washington/Seattle Cancer Chief, Department of Dermatology Center Director, Melanoma Program, MGH Cancer Center David Polsky, MD, PhD Director, Cutaneous Biology Research Center Associate Professor of Dermatology and Massachusetts General Hospital Pathology Edward Wigglesworth Professor of Director, Pigmented Lesion Section Dermatology, Harvard Medical School NYU Langone Medical Center

Thomas Gajewski, MD, PhD Antoni Ribas, MD, PhD Professor, Departments of Pathology and Professor of Medicine, University of California Medicine University of Lynn Schuchter, MD Jeffrey Gershenwald, MD C. Willard Robinson Professor of Hematology- Professor, University of Texas M.D. Anderson Oncology Cancer Center Attending Physician, Hospital of the University of Pennsylvania F. Stephen Hodi, MD Program Leader, Melanoma Program, Associate Professor, Department of Medicine, Abramson Cancer Center Harvard Medical School Division Chief, Hematology-Oncology, Director, Melanoma Center, Dana-Farber Cancer Institute Susan Swetter, MD Professor of Dermatology Sancy Leachman, MD, PhD Director, Pigmented Lesion & Melanoma Professor and Chair, Department of Program Dermatology Stanford University Medical Center and Director, Melanoma Research Program, Knight Cancer Institute Cancer Institute, Oregon Health and Science University Suzanne Topalian, MD Professor of Surgery and Oncology, Roger Lo, MD, PhD Johns Hopkins Medicine; Director, Melanoma Clinic in Dermatology Director, Melanoma Program, Sidney Kimmel Assistant Clinical Professor of Medicine, Comprehensive Cancer Center Dermatology, UCLA Jedd Wolchok, MD, PhD Associate Attending Memorial Sloan-Kettering Cancer Center

Melanoma Research Alliance Progress Report 25 www.curemelanoma.org Grant Review Committee

David Solit, MD – Chair Glenn Dranoff, MD Associate Attending Physician, Genitourinary Director, Human Gene Transfer Laboratory Oncology Service; Associate Member, Human Core, Dana-Farber Cancer Institute Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center David Fisher, MD, PhD Associate Professor of Medicine, Weill Cornell Chief, Dermatology Service Medical College Director, Melanoma Program, MGH Cancer Associate Professor of Cell and Center Developmental Biology, Weill Cornell Director, Cutaneous Biology Research Center; Graduate School of Medical Sciences at Massachusetts General Hospital Cornell University Thomas Gajewski, MD, PhD Kim Margolin, MD – Co-Chair Associate Professor, Departments of Physician, Pathology and Medicine, University of University of Washington/Seattle Cancer Chicago Center Director, Immunology and Cancer Program, University of Chicago Comprehensive Cancer Marcus Bosenberg, MD, PhD Center Associate Professor of Dermatology and Pathology, Levi Garraway, MD, PhD Yale School of Medicine Associate Professor of Medicine, Dana-Farber Cancer Institute; Steven Burakoff, MD Associate Member, Broad Institute Professor of Medicine, Hematology and Medical Oncology; Professor, Oncological Jeffrey Gershenwald, MD Sciences, Professor Mount Sinai School of Medicine University of Texas M.D. Anderson Cancer Center Paul Chapman, MD Attending Physician, Melanoma/Sarcoma Allan C. Halpern, MD service, Memorial Sloan-Kettering Cancer Chief, Dermatology Service, Center; Professor of Medicine, Weill Medical Memorial Sloan Kettering Cancer Center College of Cornell University Meenhard Herlyn, DVM, DSc Tanja de Gruijl, PhD Professor and Program Leader, Associate Professor, Molecular and Cellular Oncogenesis Program, VU University Medical Center 487 Wistar Institute

Charles Drake, MD, PhD Thomas Hornyak, MD, PhD Associate Professor, Oncology, Chief, Dermatology, VA Maryland Health Care Immunology and Urology; System; Associate Professor of Dermatology Director - Multidisciplinary Prostate Cancer and Biochemistry and Molecular Biology Clinic, Johns Hopkins Sidney Kimmel University of Maryland School of Medicine Comprehensive Cancer Center

Melanoma Research Alliance Progress Report 26 www.curemelanoma.org Roger Lo, MD, PhD Stan Riddell, MD Director, Melanoma Clinic in Dermatology; Member, Department of Immunology, Assistant Professor, Department of Medicine, Fred Hutchinson Cancer Research Center Dermatology; Assistant Professor, Department of Molecular Caroline Robert, MD, and Medical Pharmacology Professor of Dermatology University of California, Los Angeles, School of Head of the Dermatology Unit Medicine Institute Gustave Roussy

Michal Lotem, MD Lynn Schuchter, MD Senior Physician, C. Willard Robinson Professor of Hematology- Sharett Institute of Oncology, Oncology Hadassah Hebrew University Hospital Attending Physician, Hospital of the University of Pennsylvania Richard Marais, PhD Program Leader: Melanoma Program, Director Abramson Cancer Center of the University of Paterson Institute for Cancer Research Pennsylvania Division Chief, Hematology-Oncology, Grant McArthur, MBBS, PhD, FRACP University of Pennsylvania Professor; Co-chair, Melanoma and Skin Service Jonathan Simons, MD Head, Molecular Oncology Laboratory; CEO and President, Head, Translational Research Laboratory; David H. Koch Chair, Peter MacCallum Cancer Centre Prostate Cancer Foundation

Martin McMahon, PhD Alan Spatz, MD Professor-In-Residence Professor, Jewish General Hospital/Lady Davis University of California, San Francisco Institute for Medical Research

Glenn Merlino, PhD Suzanne Topalian, MD Chief, Laboratory of Cancer Biology and Professor of Surgery and Oncology, Genetics, Johns Hopkins Medicine; National Cancer Institute, NIH Director, Melanoma Program, Sidney Kimmel Comprehensive Cancer Center Drew Pardoll, MD, PhD Co-Director, Cancer Immunology and Hematopoiesis Program, Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics, John Hopkins University School of Medicine

Antoni Ribas MD, PhD Associate Professor, Department of Medicine, University of California, Los Angeles 10833 Le Conte Ave UCLA Medical Center

Melanoma Research Alliance Progress Report 27 www.curemelanoma.org